Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Former Bard execs sentencing

This article was originally published in The Gray Sheet

Executive Summary

Former Bard execs sentencing: Judge Joseph Tauro, U.S. District Court, Boston, schedules Aug. 8 sentencing of three ex-Bard executives convicted in August 1995 of conspiring to defraud FDA ("The Gray Sheet" Aug. 28, 1995, p. 2). The former execs convicted are: Bard group exec VP David Prigmore; John Cvinar, former President of Bard's USCI angioplasty catheter division; and Lee Leichter, former director of regulatory affairs and quality assurance for USCI. Former Bard CEO, George Maloney, and Kenneth Thurston, former director of regulatory affairs for USCI, were acquitted. Charges facing Janice Piasecki, a former supervisor in the regulatory affairs department, were dropped. The three defendants found guilty each face up to five years imprisonment and a fine of $250,000...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel